Influence of Anesthetic Temperature on Cephalad Sensory Blockade With Spinal Anesthesia
ATOCEB
ATOCEB
Sponsor study identifier
Secondary identifiers
interventional
400
1 country
1
Study Start
December 2008
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
November 2012
Actual (reported)Study Completion
December 2012
Actual (reported)Several factors influence the extension of anesthetic mixture during spinal anesthesia including anesthetic gravity, body position, drug volume, and drug-delivering velocity. However, the effect of temperature of anesthetic mixture on the cephalad sensory blockade is hitherto unknown. The investigators hypothesized that different temperatures of the anesthetic mixture had different velocity of extension after spinal anesthesia. In addition, previous studies suggest that parturients have relative higher sensitivity to temperature. Herein the investigators proposed that the temperature of anesthetic mixture had more extensive effect on the cephalad sensory blockade with spinal anesthesia for cesarean delivery.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 2012
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
December 2008
Date type not reportedThis date has not been verified as actual or estimated.
December 26, 2008
Actual (reported)December 29, 2008
Actual (reported)November 2012
Actual (reported)December 2012
Actual (reported)Maximum cephalad sensory blockade to pinprick, cold and touch
From the delivery of anesthetic mixture to 15 min immediate after spinal anesthesia
Velocity of the sensory blockade at identical body position
From the delivery of anesthetic mixture to 15 min immediate after spinal anesthesia
The total dose of phenylephrine required to maintain baseline arterial blood pressure
From the delivery of anesthetic mixture to 25 min after spinal anesthesia
Time interval of the occurrence of the hypotension
From the delivery of the anesthetic mixture to 25 min after spinal anesthesia
Mixture of anesthetic including hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg, with the temperature of 20 degree celsius
Mixture of anesthetic including hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg, with the temperature of 10 degree celsius
Mixture of anesthetic including hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg, with the temperature of 15 degree celsius
Hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.
Grouped treatment entry
bupivacaine/fentanyl/morphine
The registry names several treatments. This does not confirm that participants received them together or that they form a single product.
View registry recordNanjing Maternal and Child Health Care Hospital
Nanjing, Jiangsu, 210004, China
XiaoFeng Shen, MD
Nanjing Medical University
400 participants (actual enrollment reported by the registry).
First Submitted
December 26, 2008
First Posted
December 29, 2008
Study Start
December 2008
Date type not reportedThis date has not been verified as actual or estimated.
IC-CS Risk: Patient Outcomes
Mixture of anesthetic including hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg, with the temperature of 25 degree celsius
Mixture of anesthetic including hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg, with the temperature of 30 degree celsius
Mixture of anesthetic including hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg, with the temperature of 35 degree celsius
Contact the study team to confirm eligibility.
Primary Completion
November 2012
Actual (reported)Study Completion
December 2012
Actual (reported)Last Updated
January 14, 2014
Record last verified: 2014-01
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: